Lantheus (NASDAQ:LNTH) Issues Q2 Earnings Guidance

Lantheus (NASDAQ:LNTH) updated its second quarter earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $1.81-1.86 for the period, compared to the consensus estimate of $1.66. The company issued revenue guidance of $380-390 million, compared to the consensus revenue estimate of $356.88 million. Lantheus also updated its FY24 guidance to $7.00-7.20 EPS.

Lantheus Trading Down 3.4 %

LNTH traded down $2.65 during midday trading on Friday, hitting $75.53. The company’s stock had a trading volume of 1,838,111 shares, compared to its average volume of 909,698. The firm has a market cap of $5.18 billion, a P/E ratio of 11.53 and a beta of 0.52. Lantheus has a 52-week low of $50.20 and a 52-week high of $100.85. The company has a current ratio of 4.84, a quick ratio of 5.45 and a debt-to-equity ratio of 0.59. The firm has a 50-day moving average price of $62.67 and a two-hundred day moving average price of $62.76.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. The firm had revenue of $354.00 million for the quarter, compared to analysts’ expectations of $350.44 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. On average, research analysts anticipate that Lantheus will post 5.96 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on LNTH shares. Mizuho raised their price target on Lantheus from $90.00 to $100.00 and gave the company a buy rating in a report on Friday. JMP Securities reiterated a market outperform rating and issued a $100.00 price objective on shares of Lantheus in a report on Friday, February 23rd. StockNews.com cut Lantheus from a buy rating to a hold rating in a report on Friday. Truist Financial lifted their price target on Lantheus from $82.00 to $96.00 and gave the company a buy rating in a research report on Friday. Finally, B. Riley upped their price objective on Lantheus from $95.00 to $99.00 and gave the company a buy rating in a report on Thursday, April 18th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $103.14.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares in the company, valued at $16,434,804.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the stock in a transaction dated Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Insiders have sold a total of 94,545 shares of company stock worth $6,169,936 over the last 90 days. Insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.